Skip to search formSkip to main contentSkip to account menu

canakinumab 180 MG Injection [Ilaris]

Known as: CANAKINUMAB 150 mg in 1 mL SUBCUTANEOUS INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [Ilaris], ILARIS 180 MG Injection 
National Institutes of Health

Related topics

Related topics

7 relations
HistidineInjectionPolysorbate 80Sucrose

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Canakinumab (ILARIS®) in cryopyrin-associated periodic syndrome (CAPS)patients below 2 years of age: Review of four cases and literature.
Cryopyrin-Associated Periodic Syndrome (CAPS) is combination of different autoinflammatory hereditary disorders with same genetic… 
2014
2014
Опыт применения ингибитора интерлейкина 1β канакинумаба у больного с хронической тофусной подагрой
This article reports a clinical case of administration of canakinumab (Ilaris®), an interleukin-1β inhibitor, in a patient with… 
Review
2013
Review
2013
FRI0430 Comparative effectiveness and health economic evaluation of systemic anti-inflammatory therapies for acute GOUT flares
Background There have been few published comparisons of various treatment options for acute gout flares that incorporate costs… 
2013
2013
THU0392 Beta-confident-registry: Efficacy and safety of canakinumab in cryopyrin associated periodic syndrome - 18 month follow-up
Background Canakinumab (CAN, Ilaris®), a fully human anti-IL-1β monoclonal antibody, selectively inhibits IL-1β and has been… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)